CLL
MCID: CHR418
MIFTS: 49

Chronic Leukemia (CLL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Leukemia

MalaCards integrated aliases for Chronic Leukemia:

Name: Chronic Leukemia 12 54 15 71
Adult Chronic Leukemia 12
Cll 12
Cml 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1036
NCIt 49 C3483
UMLS 71 C1279296

Summaries for Chronic Leukemia

Disease Ontology : 12 A leukemia that develops slowly.

MalaCards based summary : Chronic Leukemia, also known as adult chronic leukemia, is related to chronic myelomonocytic leukemia and chronic neutrophilic leukemia. An important gene associated with Chronic Leukemia is STAT5A (Signal Transducer And Activator Of Transcription 5A), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Lorazepam and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Chronic Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Chronic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)
# Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 33.2 U2AF1 TET2 STAT5A LUC7L2 ASXL1
2 chronic neutrophilic leukemia 32.5 U2AF1 TET2 LUC7L2 ASXL1
3 leukemia 32.4 WT1 U2AF1 TET2 STAT3 CCND1 BCR
4 childhood leukemia 32.2 TET2 STAT5B STAT5A BCR
5 chronic eosinophilic leukemia 31.7 WT1 U2AF1 TET2 STAT5B STAT5A FIP1L1
6 leukemia, chronic myeloid 31.7 WT1 U2AF1 STAT5B STAT5A STAT3 PTEN
7 leukemia, chronic lymphocytic 31.6 XIAP U2AF1 TET2 STAT5B STAT5A STAT3
8 juvenile myelomonocytic leukemia 31.5 U2AF1 TET2 STAT5B STAT5A STAT3 PTEN
9 b-cell lymphoma 31.3 XIAP STAT3 CCND1 BIRC5 BCR
10 t-cell lymphoblastic leukemia/lymphoma 30.8 XIAP STAT5A STAT3 CCND1 BIRC5
11 acute leukemia 30.7 WT1 PRAME DIABLO BIRC5 BCR
12 lymphoma, non-hodgkin, familial 30.7 XIAP U2AF1 STAT3 PTEN CCND1 BIRC5
13 monoclonal gammopathy of uncertain significance 30.5 U2AF1 LUC7L2 CCND1
14 leukemia, acute lymphoblastic 30.5 XIAP WT1 U2AF1 STAT5B PRAME BCR
15 neuroblastoma 30.4 XIAP STAT3 PTGS2 PTEN DIABLO CCND1
16 burkitt lymphoma 30.4 XIAP STAT3 DIABLO CCND1 BIRC5 BCR
17 t-cell acute lymphoblastic leukemia 30.4 XIAP U2AF1 STAT5B STAT5A PTEN
18 myeloid leukemia 30.4 WT1 U2AF1 TET2 STAT5B STAT5A STAT3
19 squamous cell carcinoma 30.3 U2AF1 STAT3 PTGS2 PTEN CCND1
20 peripheral t-cell lymphoma 30.2 TET2 STAT3 PTEN CCND1
21 atypical chronic myeloid leukemia 30.1 U2AF1 TET2 LUC7L2 ASXL1
22 indolent systemic mastocytosis 30.1 U2AF1 TET2 FIP1L1 ASXL1
23 mastocytosis 30.0 TET2 STAT5B STAT5A FIP1L1 ASXL1
24 gastrointestinal stromal tumor 30.0 WT1 STAT3 PTGS2 PTEN CCND1 BCR
25 polycythemia vera 29.8 U2AF1 TET2 STAT5B STAT5A STAT3 FIP1L1
26 systemic mastocytosis 29.7 U2AF1 TET2 STAT5B STAT5A STAT3 FIP1L1
27 myeloma, multiple 29.7 XIAP U2AF1 STAT5B STAT5A STAT3 PTEN
28 myelofibrosis 29.6 WT1 U2AF1 TET2 STAT5B STAT5A STAT3
29 aplastic anemia 29.5 WT1 U2AF1 TET2 STAT3 GFI1B ASXL1
30 myelodysplastic syndrome 29.5 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
31 hematologic cancer 29.4 XIAP WT1 U2AF1 STAT5B STAT5A STAT3
32 myeloproliferative neoplasm 29.3 WT1 U2AF1 TET2 STAT5B STAT5A STAT3
33 acute promyelocytic leukemia 29.3 XIAP WT1 U2AF1 STAT5B STAT5A STAT3
34 essential thrombocythemia 29.2 U2AF1 TET2 STAT5B STAT5A STAT3 CCND1
35 leukemia, acute myeloid 28.9 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
36 cll/sll 12.4
37 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.2
38 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.2
39 leukemia, t-cell, chronic 11.2
40 subacute leukemia 11.1
41 large granular lymphocyte leukemia 10.6 STAT5B STAT3
42 glioblastoma neural subtype 10.6 STAT5B STAT5A
43 mixed lacrimal gland cancer 10.6 STAT3 CCND1
44 microcystic stromal tumor 10.6 WT1 CCND1
45 jak3-deficient severe combined immunodeficiency 10.5 STAT5B STAT5A
46 childhood malignant schwannoma 10.5 CCND1 BIRC5
47 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.5 STAT5B STAT5A STAT3
48 bowenoid papulosis 10.5 PTGS2 CCND1
49 skin papilloma 10.5 PTGS2 PTEN CCND1
50 lymphoma, hodgkin, classic 10.5

Comorbidity relations with Chronic Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Chronic Leukemia:



Diseases related to Chronic Leukemia

Symptoms & Phenotypes for Chronic Leukemia

GenomeRNAi Phenotypes related to Chronic Leukemia according to GeneCards Suite gene sharing:

26 (show top 50) (show all 61)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.13 BCR
2 Decreased viability GR00055-A-2 10.13 BCR
3 Decreased viability GR00106-A-0 10.13 FIP1L1 U2AF1
4 Decreased viability GR00221-A-1 10.13 HGF
5 Decreased viability GR00221-A-2 10.13 BCR HGF
6 Decreased viability GR00221-A-4 10.13 BCR HGF
7 Decreased viability GR00249-S 10.13 BCR BIRC5 CCND1 FIP1L1 GFI1B
8 Decreased viability GR00301-A 10.13 BCR
9 Decreased viability GR00342-S-3 10.13 BCR
10 Decreased viability GR00381-A-1 10.13 BIRC5 DIABLO WT1
11 Decreased viability GR00386-A-1 10.13 BIRC5 FIP1L1 GFI1B LUC7L2 PTEN
12 Decreased viability GR00402-S-2 10.13 BCR BIRC5 CCND1 DIABLO GFI1B U2AF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.11 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.11 PTGS2 FIP1L1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.11 XIAP
16 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10.11 STAT5B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.11 XIAP
18 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.11 PTGS2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.11 PTGS2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.11 STAT3 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.11 XIAP
22 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.11 STAT5B
23 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.11 BIRC5
24 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.11 PTGS2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.11 PTGS2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.11 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.11 PTEN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.11 WT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.11 PTEN
30 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.11 LUC7L2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.11 XIAP FIP1L1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.11 PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.11 STAT3 XIAP
34 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.11 BIRC5
35 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.11 XIAP
36 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.11 LUC7L2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.11 PTGS2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.11 STAT3
39 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.11 FIP1L1 PTEN WT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.11 XIAP
41 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.11 BIRC5
42 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.11 WT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.11 PTGS2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.11 XIAP
45 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.11 PTEN
46 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.11 WT1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.11 WT1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.11 STAT5B
49 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.11 PTGS2 FIP1L1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.11 PTEN

MGI Mouse Phenotypes related to Chronic Leukemia:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 ASXL1 BCR BIRC5 CCND1 DIABLO GFI1B
2 hematopoietic system MP:0005397 10.31 ASXL1 BCR BIRC5 CCND1 GFI1B HGF
3 growth/size/body region MP:0005378 10.27 ASXL1 BCR CCND1 DIABLO HGF PTEN
4 endocrine/exocrine gland MP:0005379 10.26 ASXL1 BIRC5 CCND1 PTEN PTGS2 SOAT1
5 homeostasis/metabolism MP:0005376 10.22 ASXL1 BCR BIRC5 CCND1 GFI1B PTEN
6 cardiovascular system MP:0005385 10.21 CCND1 GFI1B HGF PTEN PTGS2 SOAT1
7 immune system MP:0005387 10.21 ASXL1 BCR BIRC5 CCND1 GFI1B PTEN
8 liver/biliary system MP:0005370 10 ASXL1 BCR HGF PTEN PTGS2 SOAT1
9 mortality/aging MP:0010768 10 ASXL1 BCR BIRC5 CCND1 GFI1B HGF
10 integument MP:0010771 9.97 CCND1 GFI1B PTEN PTGS2 SOAT1 STAT3
11 neoplasm MP:0002006 9.56 ASXL1 CCND1 PTEN PTGS2 SOAT1 STAT3
12 normal MP:0002873 9.4 BCR BIRC5 CCND1 DIABLO PTEN PTGS2

Drugs & Therapeutics for Chronic Leukemia

Drugs for Chronic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lorazepam Approved Phase 3 846-49-1 3958
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Daunorubicin Approved Phase 3 20830-81-3 30323
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
11
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
12
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
13
Thioguanine Approved Phase 3 154-42-7 2723601
14
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
15
Lenalidomide Approved Phase 3 191732-72-6 216326
16
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
17
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
18
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
19
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
20
leucovorin Approved Phase 3 58-05-9 6006 143
21
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
22
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
24 Pevonedistat Investigational Phase 3 905579-51-3
25
Lonafarnib Investigational Phase 3 193275-84-2 148195
26 Gastrointestinal Agents Phase 3
27 Hormones Phase 3
28 Antiemetics Phase 2, Phase 3
29 Hormone Antagonists Phase 3
30 glucocorticoids Phase 3
31 Neuroprotective Agents Phase 2, Phase 3
32 Anti-Inflammatory Agents Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Analgesics Phase 3
35 Anti-Bacterial Agents Phase 3
36 Antibiotics, Antitubercular Phase 3
37 Etoposide phosphate Phase 3
38 Anti-HIV Agents Phase 3
39 Interleukin-2 Phase 3
40 Anti-Retroviral Agents Phase 3
41 Hydrocortisone 17-butyrate 21-propionate Phase 3
42 Hydrocortisone-17-butyrate Phase 3
43 Hydrocortisone hemisuccinate Phase 3
44 N-Methylaspartate Phase 3
45 BB 1101 Phase 3
46
asparaginase Phase 3
47
Homoharringtonine Phase 3 285033
48 Bendamustine Hydrochloride Phase 3
49 ON 01910 Phase 3
50 Hematinics Phase 3

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 The Effect of Special Diets on Weight and Nutritional Intake in Haematological Cancer Patients Completed NCT02880709 Phase 4
2 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Unknown status NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
3 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
4 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
5 A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT00471497 Phase 3 nilotinib;imatinib
6 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
7 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
9 A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Recruiting NCT04266301 Phase 3 MBG453;Azacitidine;Placebo
10 The Clinical Efficacy of Azacytidine Combined With HAG Regimen in Elderly Patients With Myeloid Malignancy Recruiting NCT03873311 Phase 3 Azacytidine, HAG Regimen
11 A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation Recruiting NCT03836261 Phase 3 Acalabrutinib;Venetoclax;Chemoimmunotherapy;Obinutuzumab
12 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
13 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
14 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Active, not recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
15 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
16 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
17 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
18 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
19 A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia Terminated NCT00109538 Phase 3 Lonafarnib
20 A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib Terminated NCT00519090 Phase 3 Imatinib;Nilotinib (AMN107)
21 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure Unknown status NCT01133886 Phase 2 Decitabine
22 A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
23 A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT01926587 Phase 1, Phase 2 oral rigosertib;Azacitidine
24 A Phase II Proof-of-Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive In Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies Unknown status NCT01620216 Phase 2 Dasatinib;Nilotinib;Ponatinib Hydrochloride;Sorafenib Tosylate;Sunitinib Malate
25 A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) Unknown status NCT03040401 Phase 1, Phase 2 Cohort 1, Ceplene® and Proleukin®;Cohort 2, Ceplene® and Proleukin®;Cohort 3, Ceplene® and Proleukin®
26 Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease Unknown status NCT01051115 Phase 2 Dasatinib
27 A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q Unknown status NCT00885508 Phase 2 Lenalidomide
28 A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia Completed NCT01098084 Phase 2 Decitabine
29 A Pilot Trial of OSI-461 in Patients With Chronic Lymphocytic Leukemia Completed NCT00073489 Phase 2 OSI-461
30 A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia Completed NCT01251627 Phase 2 Decitabine
31 A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia Completed NCT00136409 Phase 2 Imatinib mesylate
32 A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies Completed NCT00719836 Phase 1, Phase 2 SB1518
33 An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed NCT01736683 Phase 2 Sotatercept
34 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
35 Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine Completed NCT01083706 Phase 2 azacitidine
36 A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
37 A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML Completed NCT01664897 Phase 2 Erlotinib Hydrochloride
38 A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00451048 Phase 2 sunitinib malate
39 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
40 A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed NCT01350947 Phase 2 5-Azacitidine
41 A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
42 Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF Completed NCT01048034 Phase 2 Azacitidine;Erythropoetin
43 A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed NCT01191190 Phase 2 Ofatumumab/HDMP
44 A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML) Completed NCT01235117 Phase 2 azacitidine
45 A Phase II Study Of CCI-779 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase Completed NCT00084916 Phase 2 temsirolimus
46 Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
47 Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults: A Clinical and Biologic Study Completed NCT00015990 Phase 2 thalidomide
48 Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
49 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
50 Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm Completed NCT01101880 Phase 2 clofarabine;cytarabine

Search NIH Clinical Center for Chronic Leukemia

Genetic Tests for Chronic Leukemia

Anatomical Context for Chronic Leukemia

MalaCards organs/tissues related to Chronic Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, B Cells, Liver, Nk Cells

Publications for Chronic Leukemia

Articles related to Chronic Leukemia:

(show top 50) (show all 808)
# Title Authors PMID Year
1
[Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. 61 54
20352702 2010
2
Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. 54 61
9150348 1997
3
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. 61 54
7911548 1994
4
Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia. 61 54
8251902 1993
5
Cytogenetic and molecular changes in leukemia found among atomic bomb survivors. 54 61
1762103 1991
6
Hematological malignancies in Ukraine in post-Chernobyl era: sources of data and their preliminary analysis. 61
32430702 2020
7
Associations between genetic polymorphisms in interleukin-10 and hematological oncology: evidence from a meta-analysis. 61
31910710 2020
8
A sudden bilateral hearing loss caused by inner ear hemorrhage. 61
31178427 2020
9
Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. 61
31688455 2020
10
Chemoenzymatic Synthesis of Enantiomeric, Bicyclic δ-Halo-γ-lactones with a Cyclohexane Ring, Their Biological Activity and Interaction with Biological Membranes. 61
31935977 2020
11
Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib. 61
31701195 2019
12
Sensor array based on single carbon quantum dot for fluorometric differentiation of all natural amino acids. 61
31784824 2019
13
MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential. 61
30515779 2019
14
Effects of GST null genotypes on individual susceptibility to leukemia: A meta-analysis. 61
30659796 2019
15
Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells. 61
31231484 2019
16
THE FORECAST OF LETHAL OUTCOME IN CHRONIC LEUKEMIA PATIENTS WITH PNEUMONIA. 61
31101784 2019
17
Disparities in place of death for patients with hematological malignancies, 1999 to 2015. 61
30709864 2019
18
Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. 61
30093158 2019
19
Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia. 61
30509616 2018
20
Effects of GST variants on the risk odds of hematological malignancy: A meta-analysis. 61
30537151 2018
21
Extranodal Richter's syndrome of the urinary bladder. 61
30337788 2018
22
Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer. 61
30064854 2018
23
Pemphigus and hematologic malignancies: A population-based study of 11,859 patients. 61
29198780 2018
24
Genetic Variation of Costimulatory Molecules, Including Cytotoxic T-Lymphocyte Antigen 4, Inducible T-Cell Costimulator, Cluster Differentiation 28, and Programmed Cell Death 1 Genes, in Iranian Patients With Leukemia. 61
29697355 2018
25
Expression of aberrant antigens in hematological malignancies: A single center experience. 61
29805426 2018
26
MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. 61
29493383 2018
27
Targeted drug delivery for tumor therapy inside the bone marrow. 61
29182960 2018
28
Ocular Manifestations in Leukemias and Their Correlation with Hematologic Parameters at a Tertiary Care Setting in South India. 61
31047297 2018
29
Cancer in Kenya: types and infection-attributable. Data from the adult population of two National referral hospitals (2008-2012). 61
32382698 2018
30
Therapeutic targeting of CK2 in acute and chronic leukemias. 61
28951560 2018
31
[Molecular markers of the oral mucosa damage in patients with leukemia.] 61
30702225 2018
32
Purification of polysaccharide from artificially cultivated Anoectochilus roxburghii (wall.) Lindl. by high-speed counter current chromatography and its antitumor activity. 61
28892307 2017
33
Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans. 61
28654153 2017
34
[Clinical Application Value of Peripheral Blood Diagnostic Report]. 61
29061005 2017
35
GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. 61
28982856 2017
36
Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! 61
28546462 2017
37
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. 61
28174232 2017
38
Indwelling Pleural Catheters for Patients with Hematologic Malignancies. A 14-Year, Single-Center Experience. 61
28326798 2017
39
Pulmonary Manifestations of Lymphoma and Leukemia. 61
28477632 2017
40
Atypical chronic myeloid leukemia in a German Shepherd Dog. 61
28205462 2017
41
Differential Expression of Circadian Genes in Leukemia and a Possible Role for Sirt1 in Restoring the Circadian Clock in Chronic Myeloid Leukemia. 61
30210557 2017
42
Correlation of Cadmium and Magnesium in the Blood and Serum Samples of Smokers and Non-Smokers Chronic Leukemia Patients. 61
27511371 2017
43
Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. 61
27888540 2017
44
Noninvasive Ventilation in Patients With Hematologic Malignancy. 61
28142306 2017
45
Leukocytosis and Leukemia. 61
27866578 2016
46
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. 61
27579615 2016
47
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. 61
27229716 2016
48
A Systematic Review of Psychometric Properties of Health-Related Quality-of-Life and Symptom Instruments in Adult Acute Leukemia Survivors. 61
26645111 2016
49
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. 61
27400009 2016
50
Your patient has chronic leukemia: Now what? 61
27505878 2016

Variations for Chronic Leukemia

Expression for Chronic Leukemia

Search GEO for disease gene expression data for Chronic Leukemia.

Pathways for Chronic Leukemia

Pathways related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 XIAP STAT5B STAT5A STAT3 PTEN HGF
2
Show member pathways
13.34 STAT5B STAT5A STAT3 PTGS2 HGF CCND1
3
Show member pathways
12.86 XIAP STAT3 PTGS2 PTEN HGF CCND1
4
Show member pathways
12.75 STAT5B STAT5A STAT3 PTEN CCND1 BIRC5
5
Show member pathways
12.73 STAT5B STAT5A STAT3 PTEN CCND1 BIRC5
6
Show member pathways
12.69 XIAP STAT3 PTGS2 PTEN HGF
7
Show member pathways
12.59 STAT5B STAT5A STAT3 PTEN HGF CCND1
8
Show member pathways
12.53 STAT5B STAT5A STAT3 PTEN HGF CCND1
9 12.47 STAT5B STAT5A STAT3 PTGS2 PRAME GFI1B
10
Show member pathways
12.45 STAT5B STAT5A STAT3 PTEN CCND1
11 12.28 STAT5B STAT5A STAT3 CCND1
12 12.26 XIAP STAT5B STAT5A PTEN CCND1
13
Show member pathways
12.19 XIAP STAT5B STAT5A STAT3
14 12.17 STAT3 PTGS2 CCND1 BIRC5
15 12.16 STAT5B STAT5A STAT3 PTEN
16
Show member pathways
12.14 STAT5B STAT5A STAT3 PTEN
17
Show member pathways
12.13 STAT5B STAT5A STAT3 BCR
18
Show member pathways
12.08 STAT5B STAT5A STAT3
19 12.05 XIAP STAT5B STAT5A STAT3 PTGS2 PTEN
20
Show member pathways
12.02 STAT5B STAT5A STAT3 PTEN CCND1 BIRC5
21
Show member pathways
11.9 STAT5B STAT5A STAT3
22 11.87 STAT5B STAT5A STAT3 CCND1
23 11.87 STAT5B STAT5A STAT3 CCND1
24
Show member pathways
11.85 XIAP STAT5B STAT5A STAT3
25
Show member pathways
11.83 STAT5B STAT5A STAT3
26 11.82 STAT3 PTEN CCND1
27 11.81 XIAP PTGS2 PTEN CCND1
28
Show member pathways
11.79 STAT5B STAT5A STAT3 BCR
29
Show member pathways
11.78 XIAP DIABLO BIRC5
30 11.74 STAT5B STAT5A STAT3
31 11.71 STAT3 PTGS2 HGF CCND1 BIRC5
32 11.67 STAT5B STAT5A STAT3
33
Show member pathways
11.64 PTGS2 CCND1 BIRC5
34 11.57 XIAP PTEN CCND1
35 11.53 STAT5B STAT5A STAT3
36 11.49 STAT5B STAT5A STAT3
37 11.47 STAT5B STAT5A STAT3 PTEN
38
Show member pathways
11.41 STAT5B STAT5A STAT3
39 11.41 STAT3 PTGS2 CCND1 BIRC5
40 11.37 STAT5B STAT5A STAT3
41
Show member pathways
11.31 STAT5B STAT5A STAT3 CCND1
42
Show member pathways
11.25 STAT5B STAT5A STAT3 HGF
43
Show member pathways
11.23 STAT5B STAT5A STAT3
44 11.21 STAT5B STAT5A HGF
45 10.54 STAT5B STAT5A STAT3 CCND1

GO Terms for Chronic Leukemia

Cellular components related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
2 nucleoplasm GO:0005654 9.47 XIAP WT1 U2AF1 STAT5B STAT5A STAT3

Biological processes related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 WT1 TET2 STAT5B STAT5A STAT3 HGF
2 positive regulation of cell proliferation GO:0008284 9.91 STAT5B STAT3 PTGS2 PTEN PRAME CCND1
3 regulation of cell proliferation GO:0042127 9.88 XIAP STAT5B STAT5A STAT3 PTGS2
4 regulation of cell cycle GO:0051726 9.85 STAT3 PTEN CCND1 BCR
5 response to organic substance GO:0010033 9.8 STAT3 PTGS2 PTEN CCND1
6 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.76 XIAP PTGS2 HGF BIRC5
7 response to peptide hormone GO:0043434 9.75 STAT5B STAT5A STAT3
8 lactation GO:0007595 9.73 STAT5B STAT5A CCND1
9 JAK-STAT cascade GO:0007259 9.71 STAT5B STAT5A STAT3
10 interleukin-7-mediated signaling pathway GO:0038111 9.7 STAT5B STAT5A STAT3
11 regulation of multicellular organism growth GO:0040014 9.69 STAT5B STAT5A STAT3
12 response to organic cyclic compound GO:0014070 9.65 TET2 STAT3 PTGS2 PTEN CCND1
13 response to leptin GO:0044321 9.61 STAT3 CCND1
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 STAT5B STAT5A STAT3
15 cellular response to leptin stimulus GO:0044320 9.6 STAT3 PTEN
16 interleukin-2-mediated signaling pathway GO:0038110 9.59 STAT5B STAT5A
17 interleukin-15-mediated signaling pathway GO:0035723 9.58 STAT5B STAT5A STAT3
18 taurine metabolic process GO:0019530 9.57 STAT5B STAT5A
19 negative regulation of apoptotic process GO:0043066 9.56 XIAP WT1 STAT5B PTGS2 PTEN PRAME
20 response to estradiol GO:0032355 9.55 STAT5B STAT3 PTGS2 PTEN CCND1
21 interleukin-9-mediated signaling pathway GO:0038113 9.5 STAT5B STAT5A STAT3
22 cytokine-mediated signaling pathway GO:0019221 9.17 STAT5B STAT5A STAT3 PTGS2 HGF CCND1

Molecular functions related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
2 enzyme binding GO:0019899 9.43 PTGS2 PTEN LUC7L2 CCND1 BIRC5 BCR
3 glucocorticoid receptor binding GO:0035259 9.16 STAT5B STAT3

Sources for Chronic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....